Past News

Opus Genetics Announces 2 Key Leadership Appointments

Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced two key appointments to its founding executive team. Ash Jayagopal, Ph.D., has joined the company as Chief Scientific Officer (CSO) and Joe Schachle...

Mike Hicks Appointed Chief Technology Officer of ValGenesis

Before joining ValGenesis, Mike served as the Chief Product & Technology Officer of Intelex Technologies and currently serves as a growth advisor for multiple startups.

BioMarin New Hires

Consistent with BioMarin's regular planning, Dr. Bernstein will succeed Geoff Nichol M.B. Ch.B., MBA, FRACP, who has served for almost five years making significant contributions to the Company's clinical development program including three product approvals.  Dr. Nichol will remain at the Company to assist with the transition and to serve in an advisory capacity on late stage clinical programs. 

Genprex Appoints Mark S. Berger, M.D. as CMO & Hemant Kumar, Ph.D. as Chief Manufacturing & Technology Officer

“It is my privilege and pleasure to welcome Mark and Hemant to our management team. Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner, Chief Executive Officer.

Dr. Sarah Teichmann FmedCci FRS Joins Transition Bio as Scientific Co-Founder

“The addition of Sarah as a Scientific Co-Founder will further accelerate our existing groundbreaking work in the field of Condensomics™ and the build-out of our capabilities,” said Kelly Martin, Executive Chairman and a Founder of the Company.

Camilla Soenderby Appointed to F2G Board of Directors

Francesco Maria Lavino, CEO of F2G Ltd, added: "Camilla's experience and successful track record in rare diseases will be invaluable as we look to maximise the potential of olorofim.

Cumulus Neuroscience Appoints Dr. Ruth McKernan CBE as Chair

Ruth McKernan, newly appointed Chair added: “The formation of Cumulus Neuroscience represents a significant opportunity to address some of the current limitations of clinical trials in dementia and other brain disorders.

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences’ Board of Directors

Chip Clark, Genocea’s President, and Chief Executive Officer said, "As we advance our pipeline, including GEN-011, our neoantigen-targeted T cell therapy for the treatment of solid tumors, we believe Jennifer’s deep industry and commercial expertise will prove invaluable to us."

Aadi Bioscience Appoints Emma Reeve to its Board of Directors

“As Aadi prepares for the potential commercialization of its investigational candidate, nanoparticle albumin-bound mTOR inhibitor, FYARRO™ (sirolimus albumin-bound nanoparticles for injectable suspension, nab-sirolimus ABI-009) for PEComa, and advances its registrational trial in patients harboring TSC1 and TSC2 inactivating alterations, the addition of Emma’s expertise in transitioning and growing a newly public oncology company will be invaluable to Aadi and her appointment will complement our recently appointed Board," said Caley Castelein, M.D., Aadi Board Chairman.

Jesse Hall MD, Appointed CMO of AltruBio

Dr. Hall’s drug-development experience will help advance AltruBio’s pipeline of biologic therapies through clinical-testing for treatment of patients with immunological disease.

Patrick Fowler New Sr VP Corporate Development and Strategy at Vericel

“Patrick is a proven corporate development leader with a strong track record of success in executing strategic transactions, as well as developing and implementing corporate and business unit strategies across a variety of therapeutic area franchises,” said Nick Colangelo, President and Chief Executive Officer of Vericel.

3 New Appointments Added to the Avacta Scientific Advisory Board of its Therapeutics Division

The three new members of the SAB are Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD, and Dr. Stéphane Champiat MD, Ph.D.

Latest News

Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

Elamipretide was previously granted rare pediatric designation, fast track designation, and orphan drug designation by the FDA, and orphan drug designation by the European Medicines Agency (EMA), for the treatment of Barth syndrome. 

Opus Genetics Announces 2 Key Leadership Appointments

Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced two key appointments...

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD. Dosing of the first patient is expected in 1Q 2022. Interim data read out is anticipated for 2H 2022.

Biotage Acquires ATDBio

The acquisition of ATDBio adds important platform solutions to Biotage within DNA and RNA oligonucleotide synthesis and purification.

Join Medical Device News Magazine's Mailing List: Receive a Weekly Recap of Device Industry News